Falsified Medical Product Alert N°2/2026
JAKAVI (ruxolitinib): falsified product alert
WHO issued this alert on three falsified batches of JAKAVI, a medicine for certain serious blood diseases, reported to WHO in May 2026. The products were sold to patients through online platforms and in at least one case supplied from a pharmacy. Blister strips from falsified AVT50 and SGL04 cartons show no batch number.1
- Issued
- 16 June 2026
- Issued by
- World Health Organization
- Name stated on packaging
- Packaging bears the JAKAVI brand of Novartis with batch numbers that Novartis says are not valid.
- Genuine manufacturer's statement
- WHO said the genuine manufacturer, Novartis, stated the batch numbers are not valid and confirmed the absence of ruxolitinib in a sample of batch AVT50 20 mg found in Türkiye.
- Countries where detected
- Iran, Russia, Türkiye
Batches named in the alert
AVT50, FNR06, SGL04
Advice as stated
Do not use the listed products. Obtain medicines only from authorised or licensed suppliers. Report adverse events, lack of effect or suspected falsification to the national regulatory authority or pharmacovigilance centre.
Names printed on falsified products are not evidence that the named company made them. Where WHO or a regulator reports the genuine manufacturer's statement, it is shown.
Sources
- World Health Organization, Medical Product Alert N°2/2026: Falsified JAKAVI (ruxolitinib) (16 June 2026)